Parallel Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Parallel Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-282	Closed	-$1K	–	2547
2019 Q3	$1K	Buy	+282	New	+$1.55K	﹤0.01%	2361
2019 Q2	–	Sell	-93	Closed	-$1K	–	2502
2019 Q1	$1K	Buy	+93	New	+$1.06K	﹤0.01%	2250
2018 Q2	–	Sell	-146	Closed	-$3K	–	2250
2018 Q1	$3K	Buy	+146	New	+$2.85K	﹤0.01%	1780

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors's FPRX Position: Q4 2019 in Review

Parallel Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2019, closing a stake of 282 shares — an estimated $1K sold.

Parallel Advisors first reported a position in FPRX in Q1 2018 and held it in 3 quarters. The position peaked at $3K in Q1 2018. 94 funds tracked by Wall St. Rank hold FPRX as of Q4 2019.

Parallel Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Parallel Advisors sold 282 Five Prime Therapeutics, Inc. shares in Q4 2019, an estimated $1K.
Parallel Advisors first reported a position in Five Prime Therapeutics, Inc. in Q1 2018 and held it in 3 quarters.
Parallel Advisors's Five Prime Therapeutics, Inc. position peaked at $3K in Q1 2018.
94 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2019.

Based on Parallel Advisors's 13F filing for Q4 2019, filed 30 Jan 2020.